Phase 3 Trial of Gilteritinib Plus Azacitidine vs. Azacitidine Alone in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Background: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...